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ABSTRACT: Phage display (PD) is frequently used to discover peptides capable of binding to biological protein targets. The
structural characterization of peptide−protein complexes is often challenging due to their low binding aﬃnities and high
structural ﬂexibility. Here, we investigate the use of hydrogen/deuterium exchange mass spectrometry (HDX-MS) to characterize
interactions of low aﬃnity peptides with their cognate protein targets. The HDX-MS workﬂow was optimized to accurately
detect low-aﬃnity peptide−protein interactions by use of ion mobility, electron transfer dissociation, nonbinding control
peptides, and statistical analysis of replicate data. We show that HDX-MS can identify regions in the two epigenetic regulator
proteins KDM4C and KDM1A that are perturbed through weak interactions with PD-identiﬁed peptides. Two peptides cause
reduced HDX on opposite sides of the active site of KDM4C, indicating distinct binding modes. In contrast, the perturbation site
of another PD-selected peptide inhibiting the function of KDM1A maps to a GST-tag. Our results demonstrate that HDX-MS
can validate and map weak peptide−protein interactions and pave the way for understanding and optimizing the binding of
peptide scaﬀolds identiﬁed through PD and similar ligand discovery approaches.
An estimated 40% of current pharmaceutical researchfocuses on the development of protein and peptide-
based drugs.1 Phage display (PD) allows the easy and rapid
discovery of protein and peptide binders to biological targets
that may be developed into drugs. Through sequential
enrichment of large DNA-encoded phage libraries, the
proverbial “needle-in-the-haystack” interacting with a given
target can be identiﬁed.2 Peptides identiﬁed by PD often bind
to biologically important sites of the protein, such as the active
site of an enzyme, and are hence good drug candidates. Beyond
competitive inhibition via active site interactions, the sequence
and/or tertiary structure of the selected peptides can also
behave as allosteric modulators of the target protein. These
allosteric modulator peptides sometimes mimic natural
allosteric binding proteins, exemplifying a phenomenon
known as “convergent evolution”.3
Unfortunately, many hits from PD screening do not show
satisfactory aﬃnity in vitro, though it has been estimated that
PD selected peptides must bind to their protein target with a
dissociation constant of 50 μM or lower in order to endure the
vigorous washing steps during biopanning.4 The reduced
aﬃnity of the synthetic peptide versus the corresponding
phage can be due to the loss of multivalency. The commonly
employed M13 phage displays peptides via its pIII coat protein
in 3−5 copies,5 and the possibility that the peptide−protein
interaction is driven not only by the monomeric peptide
sequence but also by its multimeric presentation on the phage
has been discussed extensively.6 Indeed, a recent study showed
that the tetrameric presentation of a PD selected peptide
exhibited 45-fold higher binding aﬃnity toward the target when
compared to the monomeric peptide.7
As peptides encoded by phage libraries are normally 10−20
amino acids long, they usually do not adopt a stable secondary
structure in solution but are conformationally mobile.8 Due to
their high structural ﬂexibility, it is often challenging to identify
peptide binding epitopes on proteins by conventional X-ray
Received: August 21, 2014
Accepted: October 17, 2014
Published: October 17, 2014
Article
pubs.acs.org/ac
© 2014 American Chemical Society 11734 dx.doi.org/10.1021/ac503137u | Anal. Chem. 2014, 86, 11734−11741
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
D
ow
nl
oa
de
d 
vi
a 
5.
18
6.
11
7.
10
9 
on
 O
ct
ob
er
 2
9,
 2
01
9 
at
 1
2:
07
:3
1 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
crystallography. In addition, the weak binding constants of
phage display derived peptide ligands to their target proteins
require a large excess of the weak binding peptide ligands which
might interfere with crystal formation.9 While the advantages
and information content of X-ray crystallography are
undisputed, new analytical tools are needed to dissect the
binding mode of weak binding and structurally ﬂexible peptides
and to identify false-positive hits from high-throughput
screenings originating, e.g., from binding artifacts and non-
speciﬁc interactions. Furthermore, perturbations in protein
dynamics upon peptide binding are not readily detected due to
the rigidity of crystal structures.
The hydrogen/deuterium exchange (HDX) of proteins
provides a sensitive window into the molecular interactions
and dynamics of proteins in solution. Coupling of HDX with
mass spectrometric detection (MS) has within recent years
evolved to be a popular choice to study protein−protein
interactions and transient protein folding states.10,11 Through
HDX-MS, the exchange of backbone amide hydrogens for
deuteriums can be localized to diﬀerent regions of a protein by
pepsin proteolysis of the deuterium labeled protein. Perturba-
tions to the conformation of a protein upon peptide binding,
through either direct interaction or indirect changes in
dynamics, can be detected by HDX-MS. A “perturbation site”
typically manifests itself by localized reductions in deuterium
uptake between the ligand-bound and the ligand-unbound
protein.
Here, we describe and exemplify the tailoring of HDX-MS
methodology to detect and map the perturbation sites of low
aﬃnity peptide ligands on target proteins in solution. HDX-MS
is used to validate hits from phage display screening and detect
and map the low aﬃnity interaction of three inhibitory peptides
(Peptides 1−3, Table 1) with two target proteins, KDM4C and
KDM1A, which are involved in epigenetic regulation. The
results demonstrate that HDX-MS can probe and validate weak
(micromolar KD) interactions of the PD-derived peptide
ligands with their target proteins. Rigorous analysis of replicate
HDX-MS data and comparison to a nonbinding peptide allow
for the accurate detection of low-aﬃnity binding events and
ligand-induced structural rearrangements in the target protein.
■ EXPERIMENTAL SECTION
Hydrogen/Deuterium Exchange Mass Spectrometry.
The peptides were preincubated with KDM4C (expressed and
puriﬁed as described elsewhere12) or GST-KDM1A (expressed
and puriﬁed as described elsewhere13) for 30 min in order to
allow target binding prior to deuterium labeling. Continuous
amide 1H/2H hydrogen exchange (HX) was initiated by a 10-
fold dilution of a protiated protein stock solution in the
presence or absence of ligand into the corresponding
deuterated buﬀer (HEPES (12.5 mM, pH 7.4), FeSO4 (5
μM), ascorbate (100 μM)). Nondeuterated controls were
prepared by dilution into an identical protiated buﬀer. All HDX
reactions were carried out at room temperature and contained
KDM4C (1.2 μM) or KDM1A (0.8 μM) in the absence or
presence of peptide (160 μM). At appropriate time points
(ranging from 15 s to 8 h), aliquots of the HDX reaction were
quenched by addition of an equal volume of ice-cold quenching
buﬀer (containing TRIS (1.25 M, pH 2.15) and TCEP (125
mM) for KDM4C and TRIS (1.25 M, pH 2.15), guanidine (6
M), and TCEP (250 mM) for GST-KDM1A) resulting in a
ﬁnal pH of 2.3. Quenched samples were immediately frozen
and stored at −80 °C. Samples were injected into a cooled
Waters nanoAcquity UPLC system for online pepsin digestion
and rapid desalting of the protein samples. After digestion of
the samples, the peptic peptides were trapped on a precolumn
(Waters VanGuard C18, 1.7 μm, 2.1 × 5 mm, Milford, MA,
USA) and desalted with 0.68% formic acid, pH 2.3, 150 μL/
min for 3 min. Peptides were eluted from the trap to the
analytical column (Waters XBridge C18, 1.7 μm, 1.0 mm × 100
mm) and separated with an 8−40% gradient of 0.68% formic
acid in acetonitrile (pH 2.3) over 12 min at a ﬂow rate of 40
μL/min. Positive ion-electrospray ionization mass spectra of
eluted peptides were acquired on a Waters SynaptG2 HDMS
mass spectrometer. Peptic peptides were identiﬁed in separate
experiments using collision-induced dissociation tandem mass
spectrometry performed with a data-independent (MSE)
acquisition scheme. Sequence coverage maps of peptic peptides
of KDM4C and GST-KDM1A are shown in Figures S4 and S5,
Supporting Information. The sequence coverage was 91.7%
with a redundancy of 1.84 for KDM4C and 92.6% with a
redundancy of 1.61 for KDM1A. Mass spectra were processed
using the MassLynx and DynamX software packages (Waters
Corp.); bimodal curve ﬁtting was performed using HX-
Express.14 Complete deuteration of control samples was
achieved by incubation of 60 pmol of KDM4C (40 pmol
KDM1A) in the deuterated buﬀer in the presence of 6 M
guanidine for 24 h at 30 °C. Average back exchange (i.e.,
deuterium loss) was measured as 37%. However, no corrections
were made for this deuterium loss as only the relative levels of
deuterium incorporation of all samples were compared. The
HDX of KDM4C in the presence and absence of peptide after a
10 min exchange was measured in triplicate to conﬁrm the
signiﬁcance of the detected changes in deuterium uptake.
Changes in deuterium uptake were considered signiﬁcant if
they exceeded the triple standard deviation and/or passed a
two-tailed, unpaired t-test (p < 0.05). Protein structures were
visualized using PyMOL (DeLano Scientiﬁc). ETD-HDX-MS
was performed as described elsewhere.15 For each ETD
experiment, 240 pmol of KDM4C was preincubated with
3.42 nmol of peptide 2 for 30 min and then diluted 10-fold into
deuterated buﬀer. The absence of H/D scrambling was
monitored by examining the deuterium uptake of the charge-
reduced and the deammoniated ion species.16 ETD was
performed in the trap traveling wave ion guide using 1,4-
dicyanobenzene as the ETD reagent (Sigma-Aldrich, St. Louis,
USA).
Peptide Synthesis and Testing. Peptide 1 was purchased
from GenScript USA Inc. (NJ, USA); the purity was stated by
the manufacturer to be >95%. Peptides 2 and 3 were
synthesized, puriﬁed, and characterized as described else-
where.17 The peptide sequences are shown in Table 1. For
inhibition studies on KDM1A, a peroxidase-coupled assay
monitoring hydrogen peroxide production was performed as
Table 1. Peptide Sequences Including Modiﬁcations
peptide sequence protein
1a Ac-NH-SHSEFWDWGPGGG-CONH2 KDM1A
2b NH2-ACYTRNMNQC-CONH2 KDM4C
3c NH2-CKWMADGYC-CONH2 KDM4C
4d NH2-ACKWMDDGYCGGG-CONH2 KDM4C
aLinear peptide. bCyclized between Cys2 and Cys10 by m-xylene.
cCyclized between Cys1 and Cys9 by a disulﬁde bridge. dCyclized
between Cys2 and Cys10 by a disulﬁde bridge.
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previously described.18 KDM1A expression and puriﬁcation was
carried out as described elsewhere;13 non-GST-tagged KDM1A
was purchased from BPS Biosciences (#50097). The time
courses of the reaction were measured under aerobic conditions
using a Beckman Instruments DU series 600 spectropho-
tometer equipped with a thermostat-controlled cell holder (T =
25 °C). The 100 μL reactions were initiated by addition of
enzyme (100−200 nM) to the reaction mixture (HEPES buﬀer
(50 mM, pH 7.5), 4-aminoantipyrine (0.1 mM), 3,5-dichloro-2-
hydroxybenzenesulfonic acid (1 mM), horseradish peroxidase
(0.76 μM, Worthington Biochemical Corp.), peptide 1 (100
μM), and H3K4me2 histone peptide substrate (24 μM)).
Absorbance changes were monitored at 515 nm, and an
extinction coeﬃcient of 26 000 M−1·cm−1 was used to calculate
product formation. For curve ﬁtting and data analysis,
GraphPad Prism 6.0 was used.
■ RESULTS AND DISCUSSION
Workﬂow Optimization for the Detection of Low
Aﬃnity Peptide/Protein Interactions by HDX-MS. The
general workﬂow for the discovery, validation, and analysis of
peptides by PD and HDX-MS is depicted in Scheme 1. The
traditional HDX-MS workﬂow for protein−ligand analysis had
to be adapted to allow the analysis of low aﬃnity peptide/
protein interactions. Previously published protocols for HDX-
MS of protein−ligand interactions utilize 5−10 times excess of
ligand over protein.19,20 However, these conditions are
optimized for nano- or picomolar aﬃnities between ligand
and protein; the aﬃnities of the peptide ligands tested here
were in the micromolar range. Theoretical calculations
estimating the percentage of protein-bound peptide from its
IC50 value revealed that a 130-fold molar excess of peptide
compared to the protein had to be used to ensure suﬃcient
occupancy of the protein with peptide. Further, the samples
were allowed to preincubate for 30 min at room temperature
prior to deuterium labeling to ensure equilibrium binding of the
peptide to the protein. Unfortunately, the large amount of
peptide (5−15 μg per run) led to overloading of the
chromatographic system and resulted in increased carryover
between the chromatographic runs. An extensive washing
procedure consisting of three serial gradients ﬂushing the
column of excess peptide had to be implemented to decrease
the carryover. In addition, we found that the vast excess of
peptide resulted in ion suppression; the quantitative analysis of
19 diﬀerent peptic peptides covering the whole protein
sequence of KDM4C revealed that 80% of the signal intensities
were lost upon peptide addition. Hence, higher protein
concentrations had to be used to ensure suﬃcient sequence
coverage upon ligand addition. Further, PD-derived peptides
are prone to proteolytic cleavage by pepsin because they often
have an unusually high content of aromatic amino acids.21 This
is due to the fact that the active site of an enzyme is often
composed of a hydrophobic cleft, and the free energy gained by
burying aromatic residues in this cleft drives the binding of the
peptides.22 For instance, peptic cleavage of one of the peptide
ligands resulted in truncated peptides that interfered with
detection of peptides from the target protein. In addition, signal
overlap from the multiplicity of peptic peptides from the
protein sample and synthesis impurities from the ligand sample
can give rise to interference. To circumvent these challenges,
we made use of orthogonal gas-phase separation of the peptide
ligand from the target protein peptides by ion mobility. Ion
mobility spectrometry (IMS) separates analyte ions in a drift
tube ﬁlled with a carrier gas in the presence of an electrical
ﬁeld.23 The analytes’ mobility in the drift tube depends on its
mass, size, charge, and shape. The utility of coupling IMS to the
Scheme 1. General Workﬂow for the Integration of PD Lead Discovery and Interaction Analysis of Peptides and Proteins by
HDX-MSa
aOver 3−5 rounds of biopanning, PD can enrich for one, or several, peptide−phages interacting with the immobilized target protein. The binding
peptide sequences are obtained by DNA sequencing of the enriched phages, subsequently chemically synthesized, and then tested for their in vitro
activity towards the target protein. Interaction analysis is then performed between the peptide leads and the target protein by HDX-MS. Brieﬂy,
HDX is initiated by diluting the protein in the presence or absence of peptide into a deuterated buﬀer, and after diﬀerent periods of deuterium
labeling, samples are taken and quenched. The deuterated samples are then digested, and the peptic peptides are analyzed by LC-MS and LC-MS/
MS. Diﬀerential deuterium uptake plots indicate a binding event (grey curve, free protein; red curve, peptide-bound protein). The resolution of
HDX-MS can be narrowed down from peptic peptide to single amino acid level by ETD gas-phase fragmentation.36
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HDX-MS workﬂow has been demonstrated previously;24 here
we found the increased separation capability particularly useful
in HDX-MS analyses of weak peptide−protein interactions. As
an example, Figure 1 shows a singly charged peptide ion of
interest from KDM4C with an overlapping doubly charged
peptide ion (not identiﬁed). The extracted ion chromatogram
(EIC) shows the overlapping species coeluting after 3.8 min
(Figure 1A). As shown in the right panel of Figure 1, the 2+
cluster overlaps with the 1+ cluster, making the accurate
measurement of average mass impossible. Conventional
chromatography failed to isolate the two species; however,
the use of IMS led to full separation of these species due to
diﬀerent drift times (Figure 1B).
When analyzing weak peptide−protein interactions with
dissociation constants in the micromolar range by HDX-MS,
even a large excess of peptide will not result in a fully bound
population of protein to ligand at equilibrium. Depending on
the concentrations and the dilution factor upon initiation of the
HDX reaction, the labeling reaction will typically only be
possible with 50−75% of the protein in the ligand-bound state.
Thus, changes in HDX resulting from ligand binding will be
scaled down, and the reductions in deuterium uptake upon
binding of low aﬃnity peptide ligands are likely to be small in
magnitude. To account for this, our optimized HDX-MS
workﬂow dictates a comprehensive statistical analysis from
replicate experiments, allowing the identiﬁcation of all sites that
display protection eﬀects from HDX, even if they are minor
(<0.5 D). In the cases of KDM4C and KDM1A described here,
changes in HDX ranged from 0.2 to 2 D upon ligand
interaction. In our protocol, we consider changes in deuterium
uptake to be signiﬁcant if they exceeded the triple standard
deviation and/or passed a two-tailed, unpaired t-test (p < 0.05).
We ﬁnd that these threshold values are in good agreement with
a previously published study that investigates a nonpeptidic
ligand binding to microtubulin.25
HDX-MS Analysis of the Interactions of Peptide
Ligands with the Histone Demethylases KDM1A and
KDM4C. We recently reported the discovery of several peptide
ligands binding to the two histone demethylases KDM1A and
KDM4C by phage display.17 The crystal structures of KDM1A
and KDM4C are shown in Figure 2. KDM1A belongs to the
family of ﬂavin-dependent monoamine oxidases and contains a
SWIRM domain, a FAD-binding motif, and an amino oxidase
domain, as well as a tower domain which promotes binding to
the transcription factor CoREST.26 KDM4C is a jumonji-
domain containing protein consisting of an N-terminal JmjN
and a JmjC domain, as well as two C-terminal PHD and Tudor
domains.27 In this study, a truncated, (His)6-tagged version of
KDM4C was used, only containing the catalytic core domains
JmjN and JmjC. The KDM1A protein was expressed with an
N-terminal GST-tag.
Through 4−5 rounds of biopanning against (His)6-
ccKDM4C and GST-KDM1A, phage display led to the
discovery of one peptide binding to KDM1A and two further
peptides interacting with KDM4C. These peptides were
optimized to improve their inhibitory activity on the target
proteins and their druggability; two of the second generation
peptides targeting KDM4C, as well as a ﬁrst generation peptide
directed against KDM1A, were used in this study for HDX-MS
analysis, workﬂow development, and optimization (Table 1).
Histone Demethylase KDM4C. We recently identiﬁed
two peptides (2 and 3, Table 1) interacting with KDM4C by
PD.17 In an in vitro TR-FRET demethylase assay, the inhibition
constants of these peptides were found to be in the high μM
range. In a cell-based assay, none of the peptides showed any
inhibitory activity, most probably due to insuﬃcient cellular
uptake. In order to design more cell-permeable peptidomi-
metics, we set out to determine the crystal structure of the
peptides in complex with KDM4C. Despite extensive eﬀorts, no
crystals containing the peptides could be obtained; therefore,
their binding sites were investigated by HDX-MS. Four
diﬀerent sites on KDM4C showed altered deuterium uptake
upon peptide addition, and an alanine scan revealed function-
ally important amino acids in the peptide ligands. On the basis
of these ﬁndings, the initial peptide leads were truncated and
structure optimized, and these second generation peptide
ligands (peptides 2 and 3) displayed an apparent increase in
activity by 10-fold.17 Here, we describe how HDX-MS can be
used for a comprehensive, in-depth investigation of the
diﬀerences between the initial hits from the PD and the
second generation peptide ligands. Changes in peptide binding
mode and target engagement are analyzed and validated using
our tailored HDX-MS protocol.
The mode of interaction between peptides 2 and 3 and
KDM4C was studied by HDX-MS and revealed that both
peptides led to a reduction of deuterium uptake along the
KDM4C sites 113−120 (A) and 166−174 (B); while peptide 3
additionally reduced deuterium uptake of the neighboring α-
Figure 1. EIC (A) and corresponding ion mobility spectrum (B) of
the KDM4C peptic peptide 113−120. The 1+ cluster of the peptide
overlaps with a 2+ cluster originating from the protein/peptide sample.
The insets show the mass spectra integrated over the indicated
chromatographic range.
Figure 2. Structural models of the peptide ligand targets KDM1A (A,
pdb 2Z3Y) and KDM4C (B, pdb 2XML) as determined by X-ray
crystallography.
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helical regions 248−275 (C) and 331−344 (D) (Figure 3). No
reduction of deuterium uptake was observed along site C in the
presence of peptide 2. The signiﬁcance of these results was
veriﬁed through triplicate measurements after 10 min of
deuterium labeling in the presence and absence of peptide
ligand. Table S1, Supporting Information, shows the numerical
values of diﬀerential deuterium uptake and their standard
deviations after 10 min HDX.
To exclude the possibility that the detected changes are due
to nonspeciﬁc binding events related to the high peptide
concentrations employed during the labeling reaction, we have
used the additional, noninhibitory peptide 4 (Table 1) to
control for nonspeciﬁc binding. No signiﬁcant diﬀerences in
deuterium uptake levels along the sites of interest were
observed upon addition of peptide 4 (Figure 3 and Table S1,
Supporting Information), conﬁrming that the observed eﬀects
indeed result from speciﬁc interactions between peptides 2−3
and KDM4C.
To further probe and reveal the full impact of peptide 2 on
KDM4C conformation and dynamics, we performed a triplicate
HDX-MS analysis of the KDM4C-peptide 2 complex across a
longer HDX time range (up to 480 min). Furthermore, a
comprehensive statistical analysis of all data was applied to
detect small yet signiﬁcant perturbations in HDX upon ligand
binding. Figure 4 shows an overview of all analyzed peptides
after 240 min of HDX where signiﬁcance was deﬁned as
changes in deuterium uptake that are bigger than the triple
standard deviation and a p < 0.05 in an unpaired, two-tailed t-
test. The complete deuterium uptake curves ± peptide 2 are
shown in the Supporting Information (Figure S1). Using this
procedure, several additional sites, 99−112, 121−135, 136−
156, 156−165, and 359−370, were identiﬁed in the vicinity of
primary identiﬁed sites with signiﬁcantly perturbed HDX in the
presence of peptide 2. Some of those reductions in HDX were
only signiﬁcant after 240 min of HDX, and the additional time
point (480 min) was used to further verify their validity (data
not shown). When mapped onto the crystal structure of
KDM4C, it becomes obvious that these peptides lay in between
the initially identiﬁed sites A and B and C and D that show
perturbed HDX upon ligand interaction (Figure S2, Supporting
Information). For the two peptic peptides KDM4C99-105 and
KDM4C104-112, overlapping with site 99−112, observed
changes in HDX were not signiﬁcant due to an elevated
standard deviation (Figure S1, Supporting Information) and
the protection eﬀects could not be conﬁrmed after 480 min due
to poor data quality. These observations emphasize the
importance of using signiﬁcance analysis when assessing
HDX-MS data from low aﬃnity ligand binding experiments.
Furthermore, the perturbation in HDX along site 359−370 was
only signiﬁcant after 10 min (Figure S1, Supporting
Information).
The peptic peptides reaching from 99−174 lay within a
functionally unassigned region between the JmjN and the
enzymatically active JmjC domain of KDM4C (Figure 4). The
other two peptic peptides showing perturbations in HDX upon
ligand interaction, KDM4C331−344 and 359−370, are partially
located within the JmjC domain.28,29 Except for Ala108, Asn125,
and Asp174, none of the functionally important residues of
KDM4C overlap with these peptides. This indicates that the
peptides are not inhibiting KDM4C through substrate
competition, a hypothesis that is supported by the atypical
inhibition kinetics displayed by analogues of peptides 2 and 3.17
Instead, it can be hypothesized that the peptides bind to
regions involved in protein−protein interaction on the surface
of KDM4C by structurally mimicking interacting proteins.
Actually, many epigenetic enzymes are known to interact with
numerous other proteins; e.g., KDM4C is known to bind the
histone deacetylases HDAC1 and −3,30 and various other
proteins have been implicated for KDM4C interaction,
supporting this assumption. The discovery of peptides
mimicking protein−protein interactions by phage display is a
well-known phenomenon termed convergent evolution.3
Peptide 2 was derived and optimized from an initial phage
display peptide scaﬀold reported previously.17 The optimization
of peptide 2 included the truncation of the peptide scaﬀold and
the insertion of m-xylene into the disulﬁde bridge. While the
initial PD peptide signiﬁcantly reduced deuterium uptake along
site D similar to peptide 3 (data not shown), a close inspection
Figure 3. Deuterium uptake plots of sites 113−120 (A), 166−174 (B),
248−275 (C), and 331−344 (D) of peptides 2 (red), 3 (blue), and 4
(green) against free KDM4C (gray curves). The crystal structure
shows KDM4A (pdb 2VD7) in complex with histone peptide substrate
(blue spheres) and the catalytic Fe2+ ion (red sphere); sites A and B
are colored red; sites C and D are shown in orange (n = 3; ∗, p < 0.05;
∗∗, p < 0.01).
Figure 4. Diﬀerential HDX-MS data for KDM4C ± peptide 2. The
domain structure of the catalytic core of KDM4C is indicated below
the x-axis; the amino acids critical for 2-OG binding are highlighted in
gray, residues involved in Fe2+ coordination are pink, Zn2+
coordinating residues are green, and residues involved in substrate
binding and/or catalytic activity are indicated in blue (n = 3, error bars
are standard deviation of the mean; ∗, p < 0.05; ∗∗, p < 0.01).
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of HDX raw data revealed that peptide 2 induced unusual HDX
kinetics in site D of KDM4C. Site D (331−344) displayed a
pronounced bimodal isotopic distribution in the presence of
peptide 2 (Figure 5) indicating the occurrence of two distinct
conformations in this region of KDM4C that interconvert with
slow dynamics (EX1 kinetics).31 Neither the original phage
display hit nor peptide 3 led to such pronounced bimodal
patterns in site D. To conﬁrm that the observed EX1
phenomenon was not due to sample carryover from previous
chromatographic runs,32 an optimized protocol consisting of 4
consecutive washing steps and a subsequent blank was
introduced to monitor and minimize sample carryover. After
this optimization, the inter-run carryover for peptide 331−344
was reduced to >0.5%, verifying that the observed peak
broadening is indeed due to EX1 exchange kinetics.
Duplicate analysis of a full HDX time course in the presence
and absence of peptide 2 according to the optimized protocol
conﬁrmed the occurrence of EX1 kinetics in the presence of
peptide 2 with a good ﬁt to a bimodal model and a change in
peak width of 4.1 ± 0.4 m/z. We note that a slight broadening
of the peak in the absence of ligand is observed around 60 min,
yet this data had a good ﬁt to a standard binomial distribution
and did not ﬁt adequately to a bimodal distribution.14 Thus, the
occurrence of two distinct populations (Figure 5) upon peptide
binding suggests that peptide 2 induces slow unfolding
dynamics in this region. An alternate explanation for the
bimodal peak pattern could be slow binding kinetics of peptide
2 (slow kon), a phenomenon that has been observed
previously.33,34
To sublocalize residues in site D involved in EX1 kinetics
upon peptide 2 interaction, the peptic peptide KDM4C331−
344 was analyzed by electron transfer dissociation (ETD)
tandem mass spectrometry. It has recently been shown that gas-
phase fragmentation by ETD can be incorporated into the
HDX-MS workﬂow to allow extraction of HDX information for
individual amino acid residues in proteins.35,36 The peptic
peptide KDM4C331−344 fragmented suﬃciently to allow a
comprehensive analysis of deuterium uptake at single amino
acid level. The c-ion series c4−c11 revealed that the perturbed
sites involved in EX1 kinetics in the presence of peptide 2 are
Figure 5. Mass spectra of KDM4C peptic peptide 331−344 in the
absence and presence of peptide 2 after diﬀerent times of HDX. The
spectra without ligand were ﬁtted to a binomial and the spectra with
ligand to a bimodal peak distribution.
Figure 6. HDX-ETD analysis of site 331−344. (A) ETD fragment ion spectra after 0 and 240 min HDX ± peptide 2. The average mass is indicated
by dashed lines. For the charge reduced species and the c7 ion, the raw data were ﬁtted to a bimodal distribution using HXExpress (population 1:
blue curves; population 2: green curves). (B) Chemical structure and observed fragment ions of KDM4C331−344. (C) Crystal structure of KDM4C
(pdb 2XML) with peptide 331−344 highlighted in orange and 359−370 in light-orange. Residues Ile336 and Asp337 are displayed as sticks.
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located in the vicinity of residue Asp337 (Figure 6A). The
irregular isotopic distribution in the c7 fragment ion spectrum
indicates that EX1 kinetics occur from Asp337 toward the C-
terminus of the peptide (Figure 6A,C). This region of 331−344
is buried underneath helix 359−370 and points toward that
neighboring helix. Helix 359−370 shows reduced HDX
(signiﬁcant only after 10 min; see Figure S1, Supporting
Information) but no EX1 exchange kinetics (data not shown).
Likely, ligand interaction induces slow folding/refolding EX1
kinetics in the underlying helical region 331−344 in an indirect
manner through helix 359−370. The ETD data support this
hypothesis, as the C-terminal half of helix 331−344 observed to
undergo slow unfolding dynamics upon peptide 2 interaction is
in the closest vicinity of helix 359−370 (Figure 6C).
Three residues in helix 359−370 settle in a box-like
arrangement (pygo-box), similar to the PHD ﬁnger of hPygol
that recognizes tri- and dimethylated H3K4 residues. It has
been hypothesized that the trimethylated K4 residue of H3 is in
the proximity of this pygo-box; however, a conformational
change in the C-terminal domain of the KDM4 family of
proteins is required to accommodate the complete substrate.
Our results appear to corroborate this hypothesis, as the
observed EX1-type kinetics indicate that this part of the C-
terminal domain of KDM4C possesses unusual conformational
ﬂexibility, which in turn could help facilitate the binding of
other histone substrates than tri- and dimethylated H3K9.37
Histone Demethylase KDM1A. PD identiﬁed peptide 1 as
a binder of GST-KDM1A, and the resynthesized peptide
showed mixed inhibition of GST-KDM1A in an in vitro
demethylase activity assay (Figure S3A, Supporting Informa-
tion). Analysis of the binding of peptide 1 to GST-KDM1A
using our optimized HDX-MS workﬂow revealed decreased
deuterium uptake along region 101−114 (Figure 7B,D).
Interestingly, this site resides in the GST-tag, implying that
peptide 1 eﬀectively does not interact with KDM1A but rather
with the GST protein fused to the N-terminus of KDM1A for
puriﬁcation purposes. No other peptides covering the sequence
of KDM1A displayed changes in deuterium uptake upon
peptide addition (an example is shown in Figure 7A,C). To
validate our ﬁndings from HDX-MS, a cross-aﬃnity ELISA of
the peptide-1-phage against recombinant GST protein was
performed, showing that the peptide-1-phage indeed binds the
GST protein (Figure S3C, Supporting Information). This
conﬁrms that the interaction between KDM1A101−114 and
peptide 1 detected by HDX-MS is not an artifact. Furthermore,
the inhibitory activity of peptide 1 was reassessed using
recombinant KDM1A protein without a GST-tag, and no
inhibitory activity of peptide 1 could be detected for this
KDM1A construct (Figure S3B, Supporting Information). The
inhibitory activity of peptide 1 toward GST-KDM1A can
probably be explained on the basis of the close proximity of the
GST-tag to the N-terminus of KDM1A; the binding site 101−
114 is thereby located next to the actual KDM1A protein.
The example of GST-KDM1A illustrates the identiﬁcation of
a peptide ligand by phage display that inhibits the target protein
in vitro without actually interacting with it. Though puriﬁcation
tags are an important tool in protein biochemistry and
especially the fusion of proteins with GST can assist protein
solubilization and stability,38 our ﬁndings emphasize the beneﬁt
of using small or cleavable puriﬁcation tags for proteins
employed in drug discovery. Furthermore, identiﬁed interactors
of proteins should always be validated using diﬀerent methods
and/or diﬀerent constructs of the protein. Our ﬁndings are in
accord with a previously published study showing that large
puriﬁcation tags can inﬂuence protein structure and activity and
thereby lead to the identiﬁcation of false-positives.39
■ CONCLUSIONS
Here, we report the optimization and validation of an HDX-MS
workﬂow to dissect the binding modes of phage display-derived
low-aﬃnity peptide ligands on their target proteins. Using a
panel of peptide ligands binding to the two epigenetic regulator
proteins KDM4C and KDM1A, we exemplify the advantages
and challenges of combining these two technologies. Our
results show that HDX-MS can provide an alternative analytical
tool for validating and optimizing drug scaﬀolds from high-
throughput screening methods such as phage display. The
workﬂow was optimized by implementation of IMS and ETD
to achieve better sensitivity as well as the use of a nonbinding
control peptide and statistical analysis of replicate data. As
shown by the example of KDM4C, several hits from phage
display and/or optimized peptide lead structures can be
analyzed and compared to each other. By combining HDX-
MS with ETD fragmentation, higher resolution information can
be obtained to explicitly study changes in dynamics as a
consequence of ligand interaction as we show here for peptide
2 binding to KDM4C. To our knowledge, the data presented
here is the ﬁrst example of the use of ETD to sublocalize
residues involved in slow conformational dynamics (EX1-type
kinetics) in a protein−ligand complex. There are some
advantages of this HDX-MS workﬂow compared to, i.e., X-
ray crystallography: For instance, a few hundred pmol of
protein and 1 mg of peptide will often be suﬃcient to conduct
and obtain HDX data on a protein-peptide interaction. The
eﬀects of peptide binding to the protein are measured in the
solution phase and therefore more closely reﬂect native
conditions for the target protein. Both direct and indirect
dynamic eﬀects on the target protein conformation upon ligand
binding are detected. In eﬀect, HDX-MS reveals the “dynamic”
Figure 7. Mass spectra of KDM1A peptic peptides 269−284 (A) and
101−114 (B) in the absence (black) and presence (red/blue) of
peptide 1 after diﬀerent times of HDX. Deuterium uptake plots of
269−284 (C) and 101−114 (D); gray curves indicate the deuterium
uptake in the absence of peptide 1, and red/blue curves indicate
deuterium uptake in its presence. (E) The α helix highlighted in blue
represents KDM1A269−284 (pdb 2Z3Y).
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binding site on the target protein, which provides a solution-
phase view of all backbone amide sites perturbed by peptide
interaction. The example of KDM1A shows how HDX-MS can
be used to validate hits from phage display and identify false-
positives. Finally, it should be noted that the method is quite
tolerant to molecular size, also allowing the analysis of large
complexes such as antibodies binding to protein targets.
In summary, HDX-MS can be used to study low aﬃnity
peptide/protein interactions that are not accessible by tradi-
tional structure elucidation techniques. Our ﬁndings indicate
that HDX-MS can provide a much-needed alternative analytical
tool to understand the conformational dynamics of weak
peptide−protein interactions important in both chemical
biology research and early stage drug development.
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